Claims for Patent: 6,001,630

Summary for Patent: 6,001,630

Title:	Pharmaceutical compositions of chondroitinase ABC isolated from Proteus vulgaris ATCC 6896
Abstract:	A crystallizable, purified chondroitinase ABC having a molecular weight of about 100,000 dalton by the measurement of the SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and the measurement by the gel permeation chromatography method, having alanine as the N-terminal amino acid and proline as the C-terminal amino acid is disclosed. A process for the purification of the crystallizable purified chondroitinase ABC comprising removing nucleic acid from an surfactant solution extract obtained from cells of chondroitinase ABC-producing microorganisms and chromatographically treating by concentration gradient elution using a weak cation exchange resin or a strong cation exchange resin is disclosed. A composition comprising a chondroitinase and serum albumin, gelatin, or a nonionic surfactant is used to treat disc displacement. The enzyme is isolate from Proteus vulgaris ATCC 6896.
Inventor(s):	Ichikawa; Shinichi (Kamifukuoka, JP), Torikai; Misako (Wako, JP), Miyachi; Isao (Tokorozawa, JP)
Assignee:	Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) (Tokyo, JP)
Application Number:	08/444,309
Patent Claims:	1. A composition comprising chondroitinase ABC isolated from Proteus vulgaris ATCC 6896 and serum albumin or gelatin. 2. The composition of claim 1 having a pH in the range of about 5 to about 9. 3. The composition of claim 1, wherein said chondroitinase ABC comprises purified chondroitinase ABC having a specific activity of 300 U/mg or more. 4. The composition of claim 1 wherein the amount of serum albumin or gelatin is at least 0.001 parts by weight based on the weight of the chondroitinase ABC. 5. The composition of claim 1 wherein said chondroitinase ABC comprises purified chondroitinase ABC having a specific activity of 300 U/mg or more which is substantially free of endotoxin, nucleic acids and proteases. 6. The composition of claim 1 which is in the form of a solution or a dried product. 7. The composition of claim 1 further comprising a physiologically acceptable buffer agent which is adjusted to a pH in the range of about 5 to about 9 and has a concentration of from about 1 to about 100 mM. 8. The composition of claim 7 wherein said buffer agent is selected from the group consisting of hydrochloric acid, sodium hydroxide, sodium carbonate, sodium hydrogencarbonate, phosphoric acid, potassium dihydrogenphosphate, dipotassium hydrogenphosphate, sodium dihydrogenphosphate, disodium hydrogenphosphate, aminoacetic acid, sodium benzoate, citric acid, sodium citrate, acetic acid, sodium acetate, tartaric acid, sodium tartarate, lactic acid, sodium lactate, ethanolamine, arginine, and ethylenediamine. 9. A pharmaceutical composition in injectable form comprising chondroitinase ABC isolated from Proteus Vulgaris ATCC 6896 and serum albumin or gelatin in a physiologically acceptable liquid. 10. A composition comprising chondroitinase ABC isolated from Proteus Vulgaris ATCC 6896 and a nonionic surfactant. 11. The composition of claim 10 further comprising a physiologically acceptable buffer agent having a pH in the range of about 5 to about 9 and a buffer concentration of from about 1 to about 100 mM. 12. The composition of claim 11 having a pH between about 6 and about 8 and comprising about 10 to 50 mM phosphate buffer. 13. The composition of claim 10 wherein said chondroitinase has a specific activity of about 300 U/mg or more. 14. The composition of claim 10 wherein said nonionic surfactant comprises polyoxyethylene sorbitan fatty acid ester. 15. The composition of claim 10 wherein the amount of nonionic surfactant is about 0.6 to 300 parts by weight per unit weight of the chondroitinase ABC. 16. The composition of claim 10 which is in the form of a solution. 17. A pharmaceutical composition comprising a sterile solution of chondroitinase ABC isolated from Proteus Vulgaris ATCC 6896 in admixture with serum albumin, gelatin or a nonionic surfactant and sterile water, said solution being adapted to be injected into a patient. 18. A method for treating invertebral disc displacement comprising applying to said disc at least one of the compositions of claims 1 to 17.

Details for Patent 6,001,630

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2016-12-14